Table 2.
Gastro-intestinal complications after allo-HSCT (n = 94)
| Gastro-intestinal (GI) and hepatic complications, n = 94 (77%) | n (%overall; %GICs) |
|---|---|
| Upper mucositis | 79 (65; 84) |
| Lower mucositis | 45 (37; 48) |
| Diffuse mucositis | 36 (30; 38) |
| Digestive hemorrhages | 7 (5.7; 7.4) |
| Infective diarrhea n (%) | 8 (6.5; 8.5) |
| Clostridium difficile | 3 |
| CMV | 3 |
| Escherichia coli | 1 |
| Enterococcus faecium | 1 |
| GI-aGVHD, n (%) | 35 (29; 37%) |
| Gastro-duodenal | 20 |
| Intestinal (diffuse) | 15 |
| aGVHD staging for GI symptoms | n |
| Stage 1 | 16 |
| Stage 2 | 11 |
| Stage 3 | 3 |
| Stage 4 | 5 |
| GI-aGVHD with liver involvement | 5 (4; 5.3) |
| Upper GI Stage 1 | 4 |
| Lower GI Stage 1 | 0 |
| Lower GI Stage 2 (+ 1 upper GI) | 1 |
| Lower GI Stage 3 (+ 1 upper GI) | 1 |
| Lower GI Stage 4 (+ 2 upper GI) | 3 |
| Liver Stage 1 | 2 |
| Liver Stage 2 | 1 |
| Liver Stage 3 | 2 |
| Liver Stage 4 | 0 |
| GI-aGVHD with skin involvement | 25 (20.5; 26.6) |
| Upper GI Stage 1 | 22 |
| Lower GI Stage 1 (+3 upper GI) | 3 |
| Lower GI Stage 2 (+5 upper GI) | 7 |
| Lower GI Stage 3 (+2 upper GI) | 3 |
| Lower GI Stage 4 (+2 upper GI) | 2 |
| Skin Stage 1 | 3 |
| Skin Stage 2 | 19 |
| Skin Stage 3 | 3 |
| Skin Stage 4 | 0 |
| GI-aGVHD with skin and liver involvement | 3 (2.4; 3.2) |
| aGVHD overall clinical grade (only in GI aGVHD patients) | n |
| Grade 1 | 0 |
| Grade 2 | 23 |
| Grade 3 | 6 |
| Grade 4 | 6 |
| aGVHD overall clinical grade (all patients) | |
| Grade 1 | 31 |
| Grade 2 | 25 |
| Grade 3 | 12 |
| Grade 4 | 7 |
CMV, cytomegalovirus; GI-aGVHD, gastro-intestinal-acute GVHD; GVHD, graft-versus-host disease; HSCT, hematopoietic stem cell transplant.